Industry Overview of Oncolytic Virus Therapies Market
Oncolytic virus therapies are a type of immunotherapy that harnesses the power of viruses to infect and destroy cancer cells. These therapies utilize a range of naturally occurring and genetically modified viruses, such as herpes simplex, vaccinia, adenovirus, reovirus, picornavirus, and more. By infecting cancer cells, oncolytic viruses trigger danger signals that stimulate an immune response and effectively target solid tumors, melanoma, and unresectable lesions. They specifically infect and destroy tumor cells while sparing healthy cells, making them less toxic compared to traditional chemotherapy. Oncolytic virus therapies have shown superior efficacy and the potential to extend the survival of cancer patients. As a result, they are widely utilized in hospitals, clinics, and cancer research institutes for various applications.
How Big Is the Oncolytic Virus Therapies Market?
The global oncolytic virus therapies market size reached US$ 130.4 Million in 2022. Looking forward, IMARC Group expects the market to reach a value of US$ 492.6 Million by 2028 exhibiting a CAGR of 20.90% during 2023-2028.
Oncolytic Virus Therapies Market Trends and Drivers:
The oncolytic virus therapies market is experiencing significant growth due to the widespread adoption of these therapies in the treatment of various cancers, including glioblastoma, breast, lung, and prostate. These therapies are highly valued for their potent anti-tumor properties and their ability to accurately target tumors while minimizing harm to surrounding healthy tissues. The increasing demand for oncolytic virus therapies in the treatment of melanomas, including hematological malignancies, lymphoma, leukemia, and myeloma, is further driving market growth. Additionally, patients' growing concerns about the negative effects of conventional cancer treatments such as surgery, radiotherapy, chemotherapy, and immunotherapy are contributing to the market expansion. The market is also positively influenced by a rising number of clinical studies in oncolytic viruses, including herpesvirus, adenovirus, and vaccinia, which have shown promising experimental results in the advanced stages of research. Furthermore, the demand for advanced treatments and novel therapeutics, along with government initiatives to raise awareness about the causes of cancer and promote early diagnosis, are expected to drive the oncolytic virus therapies market.
Global Oncolytic Virus Therapies Market 2023-2028 Analysis and Segmentation:
Top Key Players covered in this report are: Amgen Inc., Dnatrix Inc., Genelux Corporation, Lokon Pharma AB, Replimune Group Inc., Rigvir Ltd., Sorrento Therapeutics, Takara Bio Inc. (Takara Holdings Inc.), Targovax, TILT Biotherapeutics Ltd, Transgene SA and Vyriad.
The report segmented the market based on region, digital channel and end-use industry.
Breakup by Virus Type:
Genetically Engineered Oncolytic VirusesHerpes Simplex VirusAdenovirusVaccinia VirusOncolytic Wild-Type VirusesReovirusNewcastle Disease VirusVesicular Stomatitis VirusBreakup by Application:
Solid TumorsBreast CancerProstate CancerLung CancerGlioblastomaMelanomaHematological MalignanciesLymphomaLeukemiaMyelomaBreakup by End Use:
HospitalsSpecialty ClinicsCancer Research InstituteBreakup by Region:
North AmericaUnited StatesCanadaAsia-PacificChinaJapanIndiaSouth KoreaAustraliaIndonesiaOthersEuropeGermanyFranceUnited KingdomItalySpainRussiaOthersLatin AmericaBrazilMexicoOthersMiddle East and AfricaKey Highlights of the Report:
Market Performance (2017-2022)
Market Outlook (2023-2028)
Market Trends
Market Drivers and Success Factors
Impact of COVID-19
Value Chain Analysis
Comprehensive mapping of the competitive landscape
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Media Contact:
Company Name: IMARC Group
Contact Person: Elena Anderson
Email: [email protected]
Phone: +1-631-791-1145
Address: 134 N 4th St
City: Brooklyn
State: NY
Country: United States
Website: https://www.imarcgroup.com
Sign in to leave a comment.